TrialEuropean journal of cancer (Oxford, England : 1990)2022

Impact of trough concentrations of regorafenib and its major metabolites M-2 and M-5 on overall survival of chemorefractory metastatic colorectal cancer patients: Results from a multicentre GERCOR TEXCAN phase II study.

Benoit Rousseau et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.